You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

247 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
May 2019
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - As monotherapy for the treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
Jun 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For relapsed and refractory mantle cell lymphoma, based on criteria
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Jun 2019
Regimen
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Palliative
Jun 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Nov 2019
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Jun 2019
Regimen
Intent: Palliative
Nov 2019

Pages